Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001044960 | SCV001208786 | uncertain significance | Hereditary spastic paraplegia 11 | 2022-04-28 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 2238 of the SPG11 protein (p.Ala2238Thr). This variant is present in population databases (rs35504505, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with SPG11-related conditions. ClinVar contains an entry for this variant (Variation ID: 842530). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003160332 | SCV003875470 | uncertain significance | Inborn genetic diseases | 2023-02-14 | criteria provided, single submitter | clinical testing | The c.6712G>A (p.A2238T) alteration is located in exon 36 (coding exon 36) of the SPG11 gene. This alteration results from a G to A substitution at nucleotide position 6712, causing the alanine (A) at amino acid position 2238 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |